Johnson & Johnson Market Cap 2010-2024 | JNJ

Johnson & Johnson market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Johnson & Johnson market cap as of July 12, 2024 is $360.71B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $360.713B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $901.365B 130.27
Novo Nordisk (NVO) Denmark $637.589B 48.99
Merck (MRK) United States $323.591B 58.88
AbbVie (ABBV) United States $300.692B 15.54
AstraZeneca (AZN) United Kingdom $245.685B 21.36
Novartis AG (NVS) Switzerland $228.315B 16.19
Pfizer (PFE) United States $163.878B 20.37
Sanofi (SNY) $130.005B 12.25
Innoviva (INVA) United States $1.045B 7.34